Loading patent…
AssigneeEvogen, Inc.
InventorsTodd WALLACH, John GLEDHILL, Richard ST.CLAIR, Elizabeth BRAND
Estimating the term…
Epileptic seizures, NES, NS, PNES or NEE are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying and monitoring seizures and epilepsy, ES, NES, NS, PNES or NEE assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for diagnosing, monitoring and predicting therapeutic efficacy associated with seizures and epilepsy, ES, NES, NS, PNES or NEE in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.
A method of diagnosing ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of differentially and/or comparatively diagnosing between ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of differentially and/or comparatively diagnosing between ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of diagnosing epilepsy, ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of differentially and/or comparatively diagnosing between epilepsy, ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of differentially and/or comparatively diagnosing between epilepsy, ES, NES, NS, PNES, or NEE in a patient, the method comprising:
A method of evaluating patient epileptic seizure burden and/or frequency in a patient, the method comprising:
A method of determining the likelihood of a patient to respond to epilepsy, ES, NES, NS, PNES, or NEE treatment, the method comprising:
A method of determining the likelihood of a patient to respond to epilepsy, ES, NES, NS, PNES, or NEE treatment, the method comprising:
A method of treating epilepsy, ES, NES, NS, PNES, or NEE in a patient likely to benefit from treatment for epilepsy, ES, NES, NS, PNES, or NEE, the method comprising administering to the patient one or more therapeutic agents selected from the group consisting of parsevenol, cenobamate, ganaxolone, phenytoin, fosphenytoin, midazolam, pregabalin, acetazolamide, methsuximide, ethotoin, piracetam, nitrazepam, paraldehyde, stiripentol, vigabatrin, brivaracetam, perampanel, rufinamide, lurasidone HCl, carbamazepine, clobazam, clonazepam, diazepam, divalproex, eslicarbazepine acetate, ethosuxemide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, primidone, tiagabine, topiramate, valproic acid, zonisamide, cannabis-based drugs, and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
A method of treating epilepsy, ES, NES, NS, PNES, or NEE in a patient likely to benefit from treatment for epilepsy, ES, NES, NS, PNES, or NEE, the method comprising administering to the patient one or more of psychotherapy, cognitive therapy, behavioral therapy, and standard medical care.
A method of treating epilepsy, ES, NES, NS, PNES, or NEE in a patient having an altered blood level of one or more biomarkers selected from calbindin, CRP, cytokeratin-8, eotaxin, eotaxin-2, eotaxin-3, GM-CSF, ICAM-1, IFN-y, IL-1a, IL-1B, IL-2, IL-4, IL-5, IL-7, IL-6, IL-13, IL-12, IL-23p40, IL-12p70, IL-10, IL-8, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1a, MIP-1B, MIP-5, MMP-1, MMP-3, MMP-9, Nectin-4, osteoactivin, osteonectin, p-cadherin, SAA, SCF, TARC, TNF-R1, TNF-R2, TNF-a, TNF-B, TRAIL, VCAM-1, VEGF-A, the method comprising administering to the patient one or more therapeutic agents selected from parsevenol, cenobamate, ganaxolone, phenytoin, fosphenytoin, midazolam, pregabalin, acetazolamide, methsuximide, ethotoin, piracetam, nitrazepam, paraldehyde, stiripentol, vigabatrin, brivaracetam, perampanel, rufinamide, lurasidone HCl, carbamazepine, clobazam, clonazepam, diazepam, divalproex, eslicarbazepine acetate, ethosuxemide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, primidone, tiagabine, topiramate, valproic acid, zonisamide, cannabis-based drugs, and any pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
A method of treating epilepsy, ES, NES, NS, PNES, or NEE in a patient having an altered blood level of one or more biomarkers selected from calbindin, CRP, cytokeratin-8, eotaxin, eotaxin-2, eotaxin-3, GM-CSF, ICAM-1, IFN-y, IL-1a, IL-1B, IL-2, IL-4, IL-5, IL-7, IL-6, IL-13, IL-12XIL-23p40, IL-12p70, IL-10, IL-8, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1a, MIP-1B, MIP-5, MMP-1, MMP-3, MMP-9, Nectin-4, osteoactivin, osteonectin, p-cadherin, SAA, SCF, TARC, TNF-R1, TNF-R2, TNF-a, TNF-B, TRAIL, VCAM-1, VEGF-A, the method comprising administering to the patient one or more of psychotherapy, cognitive therapy, behavioral therapy, and standard medical care.
A system for one or more of:
A non-transitory computer readable storage medium for one or more of:
A system for one or more of:
A non-transitory computer readable storage medium for one or more of:
Dependencies are inferred from the claim text.